Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
ATAI Life Sciences N.V (NASDAQ: ATAI) closed the day trading at $2.23 up 0.45% from the previous closing price of $2.22. In other words, the price has increased by $0.45 from its previous closing price. On the day, 3.98 million shares were traded. ATAI stock price reached its highest trading level at $2.4351 during the session, while it also had its lowest trading level at $2.14.
Ratios:
For a better understanding of ATAI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.81 and its Current Ratio is at 5.81. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on November 18, 2024, Reiterated its Buy rating but revised its target price to $10 from $15 previously.
On April 03, 2024, Maxim Group Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $6.
On November 01, 2022, Loop Capital started tracking the stock assigning a Buy rating and target price of $18.Loop Capital initiated its Buy rating on November 01, 2022, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 26 ’24 when ATAI Life Sciences N.V. sold 2,660,000 shares for $6.05 per share. The transaction valued at 16,093,000 led to the insider holds 6,905,774 shares of the business.
Brand Florian sold 151,303 shares of ATAI for $290,502 on May 16 ’24. The insider now owns 328,697 shares after completing the transaction at $1.92 per share. On Apr 02 ’24, another insider, Johnson Anne Nagengast, who serves as the Chief Financial Officer of the company, sold 27,410 shares for $1.85 each. As a result, the insider received 50,708 and left with 73,590 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATAI now has a Market Capitalization of 374198464 and an Enterprise Value of 296669664. For the stock, the TTM Price-to-Sale (P/S) ratio is 1133.93 while its Price-to-Book (P/B) ratio in mrq is 2.57. Its current Enterprise Value per Revenue stands at 896.283 whereas that against EBITDA is -2.896.
Stock Price History:
The Beta on a monthly basis for ATAI is 1.20, which has changed by 0.2542373 over the last 52 weeks, in comparison to a change of 0.21313763 over the same period for the S&P500. Over the past 52 weeks, ATAI has reached a high of $2.85, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 41.62%, while the 200-Day Moving Average is calculated to be 53.29%.
Shares Statistics:
Over the past 3-months, ATAI traded about 2.28M shares per day on average, while over the past 10 days, ATAI traded about 4628540 shares per day. A total of 167.82M shares are outstanding, with a floating share count of 116.97M. Insiders hold about 30.29% of the company’s shares, while institutions hold 6.51% stake in the company. Shares short for ATAI as of 1738281600 were 11307134 with a Short Ratio of 5.06, compared to 1735603200 on 10743811. Therefore, it implies a Short% of Shares Outstanding of 11307134 and a Short% of Float of 8.83.
Earnings Estimates
The current rating of ATAI Life Sciences N.V (ATAI) is the result of assessments by 3.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.15 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.6 and -$0.86 for the fiscal current year, implying an average EPS of -$0.76. EPS for the following year is -$0.68, with 3.0 analysts recommending between -$0.59 and -$0.73.
Revenue Estimates
A total of 6 analysts have provided revenue estimates for ATAI’s current fiscal year. The highest revenue estimate was $1.8M, while the lowest revenue estimate was $300k, resulting in an average revenue estimate of $554.33k. In the same quarter a year ago, actual revenue was $214k
